These results collectively indicate UAB36 polygenic score holds promise as a therapeutic response biomarker and an independent predictor of drug resistance risk and poor survival in ER+/HER2- breast cancer patients undergoing tamoxifen treatment. Here, ERBB2 is linked to breast carcinoma.